EUCTR2016-002778-11-ES进行中（未招募）1 期
A Randomized, Double-blind, Phase 2 Trial to Assess Safety and Efficacy of Lenvatinib at Two Different Starting Doses (18 mg vs. 14 mg QD) in Combination with Everolimus (5 mg QD) in Renal Cell Carcinoma Following One Prior VEGF-Targeted Treatment
Eisai Ltd0 个研究点目标入组 306 人开始时间: 2017年5月26日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 306
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Histological or cytological confirmation of predominant clear cell RCC (original tissue diagnosis of RCC is acceptable).
- •2. Documented evidence of advanced RCC.
- •3. One prior disease progression episode on or after VEGF-targeted treatment (for example, but not limited to, sunitinib, sorafenib, pazopanib, cabozantinib, bevacizumab, axitinib, vatalanib, AV951/tivozanib) administered for the treatment of RCC. Prior PD-1/PD-L1 treatment in addition to 1 prior VEGF-targeted treatment is allowed.
- •4. At least 1 measurable target lesion according to RECIST 1.1 meeting the following criteria:
- •Lymph node (LN) lesion that measures at least 1 dimension as =1.5 cm in the short axis Non-nodal lesion that measures =1.0 cm in the longest diameter
- •The lesion is suitable for repeat measurement using computerized tomography/magnetic resonance imaging (CT/MRI). Lesions that have had external beam radiotherapy (EBRT) or locoregional therapy must show radiographic evidence of disease progression based on RECIST 1.1 to be deemed a target lesion.
- •5. Male or female subjects age =18 years (or any age >18 years if that age is considered to be an adult per the local jurisdiction) at the time of informed consent.
- •6. Karnofsky Performance Status (KPS) of =70.
- •7. Adequately controlled blood pressure (BP) with or without antihypertensive medications, defined as BP =150/90 mmHg at Screening and no change in antihypertensive medications within 1 week before Cycle 1/Day 1.
- •8. Adequate renal function defined as calculated creatinine clearance =30 mL/min per the Cockcroft and Gault formula (Appendix 1).
- •9. Adequate bone marrow function defined by:
- •Absolute neutrophil count (ANC) =1500/mm3 (=1.5 x 109/L) Platelets =100,000/mm3(=100 x 109/L) Hemoglobin =9 g/dL.
- •10. Adequate blood coagulation function defined by International Normalized Ratio (INR) =1.5 (except for subjects on warfarin therapy where INR must be =3.0 prior to randomization).
- •11. Adequate liver function defined by:
- •Total bilirubin =1.5 times the ULN except for unconjugated hyperbilirubinemia of Gilbert’s syndrome.
- •Alkaline phosphatase (ALP), alanine aminotransferase (ALT), and aspartate aminotransferase (AST) =3×ULN (in the case of liver metastases =5×ULN). Subjects with bone metastases with ALP values greater than 3 times can be included.
- •12. Subject must voluntarily agree to provide written informed consent.
- •13. Subject must be willing and able to comply with all aspects of the protocol.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 136
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 170
排除标准
- •1. More than 1 prior VEGF-targeted treatment for advanced RCC.
- •2. Subjects with Central Nervous System (CNS) metastases are not eligible, unless they have completed local therapy for at least 4 weeks and have discontinued the use of corticosteroids for this indication or are on a tapering regimen of corticosteroids (defined as =10 mg prednisolone equivalent) before starting treatment in this study. Any signs (eg, radiologic) or symptoms of brain metastases must be stable for at least 4 weeks before starting study treatment.
- •3. Active malignancy (except for RCC or definitively treated basal or squamous cell carcinoma of the skin, or carcinoma in-situ of the cervix or bladder) within the past 24 months.
- •4. Any anti-cancer treatment (except for radiation therapy, see exclusion #5) within 21 days, or any investigational agent within 30 days prior to the first dose of study drug; subjects should have recovered from any toxicity related to previous anti-cancer treatment to CTC grade 0 or 1.
- •5. Prior radiation therapy within 21 days prior to start of study treatment with the exception of palliative radiotherapy to bone lesions, which is allowed if completed 2 weeks prior to study treatment start.
- •6. Known intolerance to study drug (or any of the excipients) and/or known hypersensitivity to rapamycins (eg, sirolimus, everolimus, temsirolimus) or any of the excipients.
- •7. Subjects with proteinuria >1+ on urinalysis will undergo 24-h urine collection for quantitative assessment of proteinuria. Subjects with urine protein =1 g/24 h will be ineligible.
- •8. Fasting total cholesterol > 300 mg/dL (or > 7.75 mmol/L) and/or fasting triglycerides level > 2.5 x ULN. NOTE: these subjects can be included after initiation or adjustment of lipid-lowering medication.
- •9. Uncontrolled diabetes as defined by fasting glucose > 1.5 times the ULN. NOTE: these subjects can be included after initiation or adjustment of glucose-lowering medication.
- •10. Prolongation of QTc interval to >480 ms.
- •11. Subjects who have not recovered adequately from any toxicity and/or complications from major surgery prior to starting therapy.
- •12. Gastrointestinal malabsorption, gastrointestinal anastomosis, or any other condition that might affect the absorption of lenvatinib or everolimus.
- •13. Bleeding or thrombotic disorders or subjects at risk for severe hemorrhage. The degree of tumor invasion/infiltration of major blood vessels (eg, carotid artery) should be considered because of the potential risk of severe hemorrhage associated with tumor shrinkage/necrosis following lenvatinib therapy.
- •14. Clinically significant hemoptysis or tumor bleeding within 2 weeks prior to the first dose of study drug.
- •15. Significant cardiovascular impairment within 6 months prior to the first dose of study drug; history of congestive heart failure greater than New York Heart Association (NYHA) Class II,unstable angina, myocardial infarction or stroke, cardiac arrhythmia associated with significant cardiovascular impairment or Left ventricular ejection fraction (LVEF) below the institutional normal range as determined by screening multigated acquisition (MUGA) scan or echocardiogram.
- •16. Active infection (any infection requiring systemic treatment).
- •17.Any medical or other condition that in the opinion of the investigator(s) would preclude the subject’s participation in a clinical study.
- •18. Females who are breastfeeding or pregnant at Screening or Baseline (as documented by a positive beta-human chorion
研究者
相似试验
尚未招募
2 期
A Randomized blinded Trial to Assess the Safety and Immunogenicity of MTBVAC with BCG vaccine as a comparator in Healthy adolescent and adult populationsCTRI/2024/07/070928Bharat Biotech International Limited
进行中（未招募）
1 期
A randomized, double-blind phase II trial to assess the efficacy and safety of bicalutamide (Casodex® ) associated to ZD6474 (Zactima™ ) or to placebo in patients with castration-refractory metastatic prostate cancer without any clinical symptom related to disease progression.MedDRA version: 9.1Level: LLTClassification code 10036909Term: Prostate cancer metastaticMetastatic prostate cancerEUCTR2007-001891-35-FRAstraZeneca SAS90
进行中（未招募）
不适用
A Phase II, Double-Blind, Randomised Study to Assess the Efficacy of AZD6244 (Hyd-Sulfate) in Combination with Dacarbazine Compared with Dacarbazine Alone in First Line Patients with BRAF Mutation Positive Advanced Cutaneous or Unknown Primary MelanomaBRAF mutation positive advanced cutaneous and unknown primary melanomaMedDRA version: 9.1Level: LLTClassification code 10025654Term: Malignant melanoma of sites other than skinMedDRA version: 9.1Level: LLTClassification code 10025670Term: Malignant melanoma stage IIIMedDRA version: 9.1Level: LLTClassification code 10025671Term: Malignant melanoma stage IVMedDRA version: 9.1Level: LLTClassification code 10027152Term: Melanoma of skin (malignant)MedDRA version: 9.1Level: LLTClassification code 10027480Term: Metastatic malignant melanomaEUCTR2008-006344-19-HUAstraZeneca AB
进行中（未招募）
1 期
A Phase II, Double-Blind, Randomised Study to Assess the Efficacy of AZD6244 (Hyd-Sulfate) in Combination with Dacarbazine Compared with Dacarbazine Alone in First Line Patients with BRAF Mutation Positive Advanced Cutaneous or Unknown Primary MelanomaBRAF mutation positive advanced cutaneous and unknown primary melanomaMedDRA version: 9.1Level: LLTClassification code 10025654Term: Malignant melanoma of sites other than skinMedDRA version: 9.1Level: LLTClassification code 10025670Term: Malignant melanoma stage IIIMedDRA version: 9.1Level: LLTClassification code 10025671Term: Malignant melanoma stage IVMedDRA version: 9.1Level: LLTClassification code 10027152Term: Melanoma of skin (malignant)MedDRA version: 9.1Level: LLTClassification code 10027480Term: Metastatic malignant melanomaEUCTR2008-006344-19-CZAstraZeneca AB91
进行中（未招募）
1 期
A Phase II, Double-Blind, Randomised Study to Assess the Efficacy of AZD6244 (Hyd-Sulfate) in Combination with Dacarbazine Compared with Dacarbazine Alone in First Line Patients with BRAF Mutation Positive Advanced Cutaneous or Unknown Primary MelanomaBRAF mutation positive advanced cutaneous and unknown primary melanomaMedDRA version: 9.1 Level: LLT Classification code 10025654 Term: Malignant melanoma of sites other than skinMedDRA version: 9.1 Level: LLT Classification code 10025670 Term: Malignant melanoma stage IIIMedDRA version: 9.1 Level: LLT Classification code 10025671 Term: Malignant melanoma stage IVMedDRA version: 9.1 Level: LLT Classification code 10027152 Term: Melanoma of skin (malignant)MedDRA version: 9.1 Level: LLT Classification code 10027480 Term: Metastatic malignant melanomaEUCTR2008-006344-19-GBAstraZeneca AB91